SCHEMBL95361

SCHEMBL95361

COc1ccc(OC=O)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.61
CA12 O43570 2/20 0.61
CA1 P00915 2/20 0.61
CA7 P43166 2/20 0.61
CA9 Q16790 2/20 0.61
CA14 Q9ULX7 2/20 0.61
ALDH1A1 P00352 3/20 0.53
TSHR P16473 3/20 0.53
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090985 0.86 CA12 (0.65) CA2CA12CA1CA7CA9
SCHEMBL2089116 0.86 CA12 (0.65) CA2CA12CA1CA7CA9
SCHEMBL27855901 0.86 CA12 (0.46) CA2CA12CA1CA7CA9
SCHEMBL2761677 0.86 MAPK1 (0.46) CA2CA12CA1CA7CA9
SCHEMBL27993733 0.84 TNFSF11 (0.49) CA2CA12CA1CA7CA9
SCHEMBL27872641 0.84 CA12 (0.44) CA2CA12CA1CA7CA9
SCHEMBL2333834 0.84 TSHR (0.55) ALDH1A1TSHRTUBB4ATUBBTUBA3C
SCHEMBL14579646 0.84 ALDH1A1 (0.43) CA2CA12CA1CA7CA9
SCHEMBL14788121 0.84 ALDH1A1 (0.47) CA2CA12CA1CA7CA9
SCHEMBL2089135 0.82 ALDH1A1 (0.43) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928473-A1 REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES Merck Sharp & Dohme Corp. (US) 2015-10-14 EP claimed
WO-2014088983-A1 REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES MERCK SHARP & DOHME CORP. (US) 2014-06-12 WO claimed
EP-2097370-A2 COMPOUNDS AND METHODS FOR AMINO-ALKYLENEDIOL SYNTHESIS F. Hoffmann-Roche AG (CH) 2009-09-09 EP claimed
WO-2008077799-A2 COMPOUNDS AND METHODS FOR AMINO-ALKYLENEDIOL SYNTHESIS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-03 WO claimed
US-5356914-A Cognition activators BEECHAM GROUP P.L.C. (GB) 1994-10-18 US claimed
EP-0552213-A1 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES BEECHAM GROUP PLC (GB) 1993-07-28 EP claimed
WO-1992006959-A1 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES BEECHAM GROUP PLC (GB) 1992-04-30 WO claimed
CN-118326723-A Color ink for spinning and preparation method thereof 珠海华彩新材料科技有限公司 2024-07-12 CN disclosed
EP-4396176-A1 INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS GENZYME CORPORATION (US) 2024-07-10 EP disclosed
EP-4396179-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION (US) 2024-07-10 EP disclosed
WO-2024137705-A1 2-HYDROXY AND 4-HYDROXY GLYCOLIPIDS AND THEIR DERIVATIVES GlycoSurf, Inc. (US) 2024-06-27 WO disclosed
WO-2024044657-A1 BIOCATALYSTS AND METHODS THEREOF TESARO, INC. (US) 2024-02-29 WO disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
WO-2001029041-A1 ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE F. HOFFMANN-LA ROCHE AG (CH) 2001-04-26 WO disclosed
WO-2000034313-A1 PROCOLLAGEN C-PROTEINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-15 WO disclosed
EP-0853497-A2 MATRICES WITH MEMORIES, SENSORS WITH MEMORIES AND USES THEREOF Irori (US) 1998-07-22 EP disclosed
WO-1997012680-A9 MATRICES WITH MEMORIES, SENSORS WITH MEMORIES AND USES THEREOF 1998-02-26 WO disclosed
WO-1997012680-A2 MATRICES WITH MEMORIES, SENSORS WITH MEMORIES AND USES THEREOF IRORI (US) 1997-04-10 WO disclosed
US-5356914-A Cognition activators BEECHAM GROUP P.L.C. (GB) 1994-10-18 US disclosed
WO-1992006959-A1 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES BEECHAM GROUP PLC (GB) 1992-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 CA2 880/4885CA12 1230/4885CA1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.